Welcome
Support Centre
29 August 2008 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
UKCTG
mental health register
archived registers
all registers
tips on searching
 
Registration
submit trials
 
Information
about mRCT
mRCT FAQs
data items
memorandum
contributors

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
'Prehab' or 'Rehab'? Minimising the loss of lean body mass after curative gastrointestinal resection and speeding rehabilitation by exercise and optimised nutrition
Source of recordUK Clinical Trials Gateway
ISRCTNISRCTN17506204
Date ISRCTN assigned29/09/2006
Local reference number(s)N0077170542
Public title'Prehab' or 'Rehab'? Minimising the loss of lean body mass after curative gastrointestinal resection and speeding rehabilitation by exercise and optimised nutrition
Scientific title
AcronymN/A
Disease/condition/study domainCancer: Gastrointestinal
Study hypothesisTo determine if patients scheduled for a curative resection of a gastrointestinal tumour are able to overcome the demands of surgery and metabolic derangements associated with it, more easily, following an optimized nutrition and resistance training programme. The expediated rehabilitation will be judged by body composition, cardiovascular and muscle function and anabolic responses of muscle and whole body protein metabolism. They will be compared with patients receiving only the current best standard care.
Design/methodologyRandomised controlled trial
Research ethics reviewNo ethics information provided as of 29 September 2006
Countries of trialUnited Kingdom
Participants - inclusion criteriaDuring a routine NHS visit 76 patients who have been identified as suitable patients at multidisciplinary team (MDT) meetings and are agreeable to participating will receive informed consent.

Inclusion Criteria: patients with curative colonic cancer.
Participants - exclusion criteria1. Metastatic disease
2. Too weak to manage the exercise
3. Unable to give informed consent
4. Patients with insufficient command of the English language
5. Patients taking steroids or betablockers
Patient information material
Anticipated start date01/11/2005
Anticipated end date01/10/2006
Status of trialCompleted
Target number of participants76
InterventionsDuring a routine NHS 76 patients who have been identified as suitable patients at MDT meetings and are agreeable to participating will receive informed consent. Screening investigations will be performed.
Patients will be randomised into two groups; a treatment group and a control group. The treatment group will enter into an eight week fitness regimen consisting of resistance exercises for twenty minutes three times a week followed by a high energy/ high protein food bar.
The control group will receive advice on nutrition and exercise alone.
There will be two study days for all patients in the study. These will be separated and may be either pre and post intervention of pre and post operative.
On each study day DEXA scanning will be performed and fractional synthetic rate determined in fasted and fed states.
All subjects will attend 7 days after their last acute study. A general examination will be performed with particular attention pain to sites of cannulation and muscle biopsies.
Recent similar studies have attracted large numbers of patients, suggesting that they will be recruitable. Opinions from patients with gastrointestinal cancer have been obtained regarding the study design and information sheets.
Primary outcome measure(s)Difference in factional synthetic rate as determined by incorporation of leucine and D%-Phenyalanine between treatment group and control group. Quantification of NFf>>B expression, mTOR and p70S6 kinase phosphorylation and protein expression in muscle samples by western analysis.
Secondary outcome measure(s)Not provided at time of registration
Sources of fundingDerby Hospitals NHS Foundation Trust
NHS R&D Support Funding
Sponsor nameRecord Provided by the NHSTCT Register - 2006 Update - Department of Health
Sponsor detailsThe Department of Health, Richmond House, 79 Whitehall
London
United Kingdom
SW1A 2NL
Sponsor telephone+44 (0)20 7307 2622
Sponsor emaildhmail@doh.gsi.org.uk
Sponsor websitehttp://www.dh.gov.uk/Home/fs/en
Contact nameProf M Larvin
Contact detailsSouthern Derbyshire Acute Hospitals NHS Trust - DCGH
Derby City General Hospital
Uttoxeter Road

Derby
United Kingdom
DE22 3NE
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN17506204
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
terms & conditions | privacy statement | © Current Controlled Trials Ltd


BioMed Central